Trial Profile
Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE) in Cystic Fibrosis Patients With Chronic Infections Due to Pseudomonas Aeruginosa
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jun 2019
Price :
$35
*
At a glance
- Drugs Amikacin (Primary)
- Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
- Focus Adverse reactions
- Sponsors Transave
- 18 Jun 2010 Status changed from recruiting to completed.
- 18 Jun 2010 Results of the open-label extension of this trial have been presented at the 33rd European Cystic Fibrosis Society (ECFS), according to a Transave media release.
- 13 Jun 2008 Added Transave as a sponsor, from Transave media release.